HHS has rescinded its approval of a major charity, Caring Voice Coalition, after the charity allowed pharma donors improper influence over the nonprofit.
HHS has rescinded its approval of a major charity, Caring Voice Coalition, after the charity allowed pharma donors improper influence over the nonprofit.
According to a letter from HHS’ Office of the Inspector General (OIG), the charity provided drug makers with data that could allow them to see if their contributions were assisting their own customers, potentially giving companies “greater ability to raise the prices of their drugs while insulating patients from the immediate out-of-pocket effects.”
Under federal law, drug companies cannot give direct co-pay assistance to patients covered by Medicare because such a practice could steer patients from one drug to another. Drug makers can, however, donate to independent charities that help cover drug costs of Medicare patients if they do not influence the operations of those charities.
The OIG said that, “effective immediately,” it is rescinding its previous approval of the charity. Caring Voice “allowed donors to directly or indirectly influence the identification or delineation” of its disease categories, which contradicted previous reports that it would not do so, said the letter. OIG’s findings are similar to issues brought to light by Bloomberg Businessweek in May 2016, which found that Caring Voice gave special treatment to patients of some company donors.
The decision to eliminate Caring Voice’s approval comes amid a wide-ranging investigation by the Justice Department into pharma’s influence over charities. Jazz pharmaceuticals has recently received three subpoenas from the Justice Department relate to its relationship with co-pay charities. Celgene Corp., United Therapeutics Corp., Pfizer Inc., and Gilead Sciences Inc., have also received similar subpoenas.
According to Bloomberg, Caring Voice may be forced to close after having its approval rescinded, potentially impacting patients’ ability to pay for expensive medications.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.